Table 2.
Cancer diagnosis and treatment characteristics.
| Patients with cancer (N = 93) | |
|---|---|
| Cancer type N (%) | |
| Gastrointestinal | 40 (43.0) |
| Breast | 23 (24.7) |
| Lung | 9 (9.7) |
| Melanoma | 10 (10.8) |
| Genitourinary | 7 (7.5) |
| Othera | 4 (4.3) |
| Cancer stage N (%) | |
| Locoregional | 31 (33.3) |
| Metastatic | 62 (66.7) |
| Cancer treatment N (%) | |
| Chemotherapyb | 31 (33.3) |
| Biologic agentc | 13 (14.0) |
| Hormonal therapyd | 3 (3.2) |
| Immunotherapye | 16 (17.2) |
| Chemotherapy + immunotherapy | 4 (4.3) |
| Chemotherapy + biologic agent | 17 (18.3) |
| Hormonal therapy + biologic agent | 5 (5.4) |
| Radiotherapy | 3 (3.2) |
| Radiotherapy + chemotherapy | 1 (1.1) |
a
Other: brain, thymoma, endometrial, and neuroendocrine.
b
Chemotherapy: Adriamycin, AC-T, AC-TPH, CMF, pemetrexed, cisplatin, carboplatin, capecitabine, paclitaxel, nab-paclitaxel, TDM-1, FOLFOX, FOLFIRI, FOLFIRINOX, gemcitabine, and vinorelbine.
c
Biologic agents: bevacizumab, panitumumab, cetuximab, palbociclib, entrectinib, abemaciclib, trastuzumab, lenvatinib, neratinib, rucaparib, osimertinib, and dabrafenib.
d
Hormonal therapy: letrozole, anastrazole, goserelin, megestrol, and octreotide.
e
Immunotherapy: pembrolizumab, nivolumab, atezolizumab, cemiplimab, ipilimumab, and durvalumab.